Literature DB >> 17951858

On the making of sharp longitudinal dose profiles with helical tomotherapy.

Michael W Kissick1, Ryan T Flynn, David C Westerly, Thomas Rockwell Mackie, Peter W Hoban.   

Abstract

Since the beam width on the helical tomotherapy machine produced by TomoTherapy Inc., is typically a few centimeters in the longitudinal direction (into the bore), the optimizer must choose to have a relatively high intensity local to the inside edge of a tumor or planning treatment volume (PTV) when avoiding an immediately adjacent organ at risk (OAR), either superior or inferior. By using a standalone version of the TomoTherapy dose calculator, a realistic beam is applied to idealized deconvolution schemes including the MATLAB Optimizer Toolbox for a simple one-dimensional PTV with adjacent OARs. The results are compared to a clinical example on the TomoTherapy planning station. It is learned that a Gibbs phenomenon type of oscillation in the dose within the tumor under these special circumstances is not unique to TomoTherapy, but is related to the attempt to form a sharp dose gradient-sharper than the beam profile with typical optimization constraints set to achieve a uniform dose as close as possible to the prescription. The clinical implication is that the Gibbs-induced cold spots force the dose to increase in the PTV if a typical PTV dose-volume constraint is used. It is recommended that the dose prescription be smoothed prior to optimization or the dosimetric goals for an OAR adjacent to the PTV are such that a sharp dose falloff is not demanded, especially if the user reduces the requirements that such an OAR be of both high importance and immediately adjacent to the PTV edge.

Entities:  

Mesh:

Year:  2007        PMID: 17951858      PMCID: PMC2220158          DOI: 10.1088/0031-9155/52/21/011

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  12 in total

1.  Tomotherapy.

Authors:  T R Mackie; J Balog; K Ruchala; D Shepard; S Aldridge; E Fitchard; P Reckwerdt; G Olivera; T McNutt; M Mehta
Journal:  Semin Radiat Oncol       Date:  1999-01       Impact factor: 5.934

2.  Accurate convolution/superposition for multi-resolution dose calculation using cumulative tabulated kernels.

Authors:  Weiguo Lu; Gustavo H Olivera; Ming-Li Chen; Paul J Reckwerdt; Thomas R Mackie
Journal:  Phys Med Biol       Date:  2005-02-21       Impact factor: 3.609

3.  The helical tomotherapy thread effect.

Authors:  M W Kissick; J Fenwick; J A James; R Jeraj; J M Kapatoes; H Keller; T R Mackie; G Olivera; E T Soisson
Journal:  Med Phys       Date:  2005-05       Impact factor: 4.071

Review 4.  History of tomotherapy.

Authors:  T R Mackie
Journal:  Phys Med Biol       Date:  2006-06-20       Impact factor: 3.609

5.  A delivery transfer function (DTF) analysis for helical tomotherapy.

Authors:  Michael W Kissick; Thomas Rockwell Mackie; Robert Jeraj
Journal:  Phys Med Biol       Date:  2007-04-10       Impact factor: 3.609

6.  Noise and edge artifacts in maximum-likelihood reconstructions for emission tomography.

Authors:  D L Snyder; M I Miller; L J Thomas; D G Politte
Journal:  IEEE Trans Med Imaging       Date:  1987       Impact factor: 10.048

Review 7.  The linear-quadratic formula and progress in fractionated radiotherapy.

Authors:  J F Fowler
Journal:  Br J Radiol       Date:  1989-08       Impact factor: 3.039

8.  Tomotherapy: a new concept for the delivery of dynamic conformal radiotherapy.

Authors:  T R Mackie; T Holmes; S Swerdloff; P Reckwerdt; J O Deasy; J Yang; B Paliwal; T Kinsella
Journal:  Med Phys       Date:  1993 Nov-Dec       Impact factor: 4.071

9.  On cold spots in tumor subvolumes.

Authors:  Wolfgang A Tomé; Jack F Fowler
Journal:  Med Phys       Date:  2002-07       Impact factor: 4.071

10.  A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density.

Authors:  S Webb; A E Nahum
Journal:  Phys Med Biol       Date:  1993-06       Impact factor: 3.609

View more
  7 in total

1.  A technique for stereotactic radiosurgery treatment planning with helical tomotherapy.

Authors:  Emilie T Soisson; Peter W Hoban; Thomas Kammeyer; Jeffrey M Kapatoes; David C Westerly; Amar Basavatia; Wolfgang A Tomé
Journal:  Med Dosim       Date:  2011       Impact factor: 1.482

2.  On the impact of longitudinal breathing motion randomness for tomotherapy delivery.

Authors:  Michael W Kissick; Ryan T Flynn; David C Westerly; Peter W Hoban; Xiaohu Mo; Emilie T Soisson; Keisha C McCall; Thomas R Mackie; Robert Jeraj
Journal:  Phys Med Biol       Date:  2008-08-18       Impact factor: 3.609

3.  Tomotherapy radiosurgery for arteriovenous malformations--current possibilities and future options with helical tomotherapy dynamic jaws?

Authors:  S Krause; S Beck; O Schramm; K Schubert; H Hauswald; A Zabel-du Bois; K Herfarth; J Debus; F Sterzing
Journal:  Technol Cancer Res Treat       Date:  2013-03-26

4.  Junctioning longitudinally adjacent PTVs with Helical TomoTherapy.

Authors:  Lourdes M Garcia; Lee H Gerig; Peter Raaphorst; David Wilkins
Journal:  J Appl Clin Med Phys       Date:  2010-04-16       Impact factor: 2.102

5.  Investigation of probabilistic optimization for tomotherapy.

Authors:  Michael W Kissick; Thomas R Mackie; Ryan T Flynn; Xiaohu Mo; David D Campos; Yue Yan; Donghui Zhao
Journal:  J Appl Clin Med Phys       Date:  2012-09-06       Impact factor: 2.102

6.  Lung and liver SBRT using helical tomotherapy--a dosimetric comparison of fixed jaw and dynamic jaw delivery.

Authors:  Leonie Rudofsky; Eleanor Aynsley; Sebastian Beck; Kai Schubert; Gregor Habl; Sonja Krause; Jürgen Debus; Florian Sterzing
Journal:  J Appl Clin Med Phys       Date:  2014-05-08       Impact factor: 2.102

7.  Dosimetric comparisons of craniospinal axis irradiation using helical tomotherapy, volume-modulated arc therapy and intensity-modulated radiotherapy for medulloblastoma.

Authors:  Yangqing Sun; Gui Liu; Wen Chen; Taili Chen; Pei Liu; Qian Zeng; Jidong Hong; Rui Wei
Journal:  Transl Cancer Res       Date:  2019-02       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.